References
1. Hashemi, S., The Overexpression Of Cox2 In Wilms’ Tumor. Reviews In
Clinical Medicine, 2014. 1(1).
2. Rivera, M.N. and D.A. Haber, Wilms’ tumour: connecting tumorigenesis
and organ development in the kidney. Nat Rev Cancer, 2005.5 (9): p. 699-712.
3. Wilms’ tumor: status report, 1990. By the National Wilms’ Tumor Study
Committee. J Clin Oncol, 1991. 9 (5): p. 877-887.
4. Geenen, M.M., M.C. Cardous-Ubbink, L.C. Kremer, et al., Medical
assessment of adverse health outcomes in long-term survivors of
childhood cancer. Jama, 2007. 297 (24): p. 2705-2715.
5. Zirn, B., O. Hartmann, B. Samans, et al., Expression profiling of
Wilms tumors reveals new candidate genes for different clinical
parameters. Int J Cancer, 2006. 118 (8): p. 1954-1962.
6. Gridley, G., J.K. McLaughlin, A. Ekbom, et al., Incidence of cancer
among patients with rheumatoid arthritis. J Natl Cancer Inst, 1993.85 (4): p. 307-311.
7. Fridman, E., J.H. Pinthus, J. Kopolovic, et al., Expression of
cyclooxygenase-2 in Wilms tumor: immunohistochemical study using tissue
microarray methodology. J Urol, 2006. 176 (4 Pt 2): p.
1747-1750.
8. Kalapurakal, J.A., J.S. Dome, E.J. Perlman, et al., Management of
Wilms’ tumour: current practice and future goals. Lancet Oncol, 2004.5 (1): p. 37-46.
9. Ferrandina, G., F.O. Ranelletti, F. Legge, et al., Prognostic role of
the ratio between cyclooxygenase-2 in tumor and stroma compartments in
cervical cancer. Clin Cancer Res, 2004. 10 (9): p. 3117-3123.
10. Shono, T., P.J. Tofilon, J.M. Bruner, O. Owolabi, and F.F. Lang,
Cyclooxygenase-2 expression in human gliomas: prognostic significance
and molecular correlations. Cancer Res, 2001. 61 (11): p.
4375-4381.
11. Simonsson, M., S. Björner, A. Markkula, et al., The prognostic
impact of COX-2 expression in breast cancer depends on oral
contraceptive history, preoperative NSAID use, and tumor size. Int J
Cancer, 2017. 140 (1): p. 163-175.
12. Soslow, R.A., A.J. Dannenberg, D. Rush, et al., COX-2 is expressed
in human pulmonary, colonic, and mammary tumors. Cancer, 2000.89 (12): p. 2637-2645.
13. Denkert, C., M. Köbel, S. Pest, et al., Expression of cyclooxygenase
2 is an independent prognostic factor in human ovarian carcinoma. Am J
Pathol, 2002. 160 (3): p. 893-903.
14. Xu, X.C., COX-2 inhibitors in cancer treatment and prevention, a
recent development. Anticancer Drugs, 2002. 13 (2): p. 127-137.
15. Lee, A., J. Frischer, A. Serur, et al., Inhibition of
cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and
survival signaling. Cancer Res, 2006. 66 (8): p. 4378-4384.
16. Dome, J.S., E.J. Perlman, and N. Graf, Risk stratification for wilms
tumor: current approach and future directions. Am Soc Clin Oncol Educ
Book, 2014: p. 215-223.
17. Oku, S., M. Higashi, Y. Imazono, et al., Overexpression of
cyclooxygenase-2 in high-grade human transitional cell carcinoma of the
upper urinary tract. BJU Int, 2003. 91 (1): p. 109-114.
18. Chen, Q., N. Shinohara, T. Abe, T. Harabayashi, and K. Nonomura,
Impact of cyclooxygenase-2 gene expression on tumor invasiveness in a
human renal cell carcinoma cell line. J Urol, 2004. 172 (6 Pt
1): p. 2153-2157.
19. Giordano, G., N. Campanini, V. Donofrio, et al., Analysis of Cox-2
expression in Wilms’ tumor. Pathol Res Pract, 2008. 204 (12): p.
875-882.
20. Kinoshita, Y., A. Suminoe, H. Inada, et al., The prognostic
significance of blastemal predominant histology in initially resected
Wilms’ tumors: a report from the Study Group for Pediatric Solid Tumors
in the Kyushu Area, Japan. J Pediatr Surg, 2012. 47 (12): p.
2205-2229.
21. Beckwith, J.B., C.E. Zuppan, N.G. Browning, J. Moksness, and N.E.
Breslow, Histological analysis of aggressiveness and responsiveness in
Wilms’ tumor. Med Pediatr Oncol, 1996. 27 (5): p. 422-428.
22. Maturu, P., D. Jones, E.C. Ruteshouser, et al., Role of
Cyclooxygenase-2 Pathway in Creating an Immunosuppressive
Microenvironment and in Initiation and Progression of Wilms’ Tumor.
Neoplasia, 2017. 19 (3): p. 237-249.